Scarica l'app Stockscreener
13.40
1.94%
-0.265
Kazia Therapeutics Limited Adr Borsa (KZIA) Ultime notizie
Jorey Chernett (NASDAQ: KZIA) reports multi-million ADS stake - Stock Titan
Ikarian Capital (KZIA) discloses 575,778 Kazia Therapeutics ADSs under 4.9% cap - Stock Titan
Kazia Therapeutics (KZIA) investor group reports 4.6% beneficial stake via ADS - Stock Titan
Kazia Therapeutics (KZIA) Holds Near $13.95 as Biotech ADR Consolidates Between Key LevelsParabolic SAR - Vinanet
Kazia files patent for breast cancer treatment strategy By Investing.com - Investing.com Nigeria
Kazia Therapeutics (NASDAQ: KZIA) files patent backed by TNBC data - Stock Titan
KZIA|Kazia Therapeutics Ltd|Price:12.802|Chg%:+0.542 - TradingKey
Kazia Therapeutics (KZIA) grants director 100,000 stock options - Stock Titan
KAZIA (NASDAQ: KZIA) CEO receives 150K RSUs and 500K stock options grant - Stock Titan
Kazia Therapeutics (KZIA) grants 150,000 stock options to VP Finance - Stock Titan
Kazia Therapeutics (KZIA) director awarded 100,000 ADS stock options - Stock Titan
Kazia Therapeutics (KZIA) grants 100,000 ADS options to CMC director - Stock Titan
Kazia Therapeutics (KZIA) director awarded 75,000 ADS stock options at $6.78 - Stock Titan
BTIG initiates Kazia Therapeutics stock with buy on cancer drug By Investing.com - Investing.com Nigeria
BTIG initiates Kazia Therapeutics stock with buy on cancer drug - Investing.com
Kazia Therapeutics Ltd Sponsored ADR Actuals & Estimates (NASDAQ:KZIA) - TradingView
Kazia Therapeutics (KZIA) awards 250,000 stock options to CSO - Stock Titan
ETFs Investing in Kazia Therapeutics Ltd Sponsored ADR Stocks - TradingView
Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Kazia Therapeutics (KZIA) Surges 13.88% as Biotech Momentum AcceleratesHot Stock Picks - DonanımHaber
KZIA News | KAZIA THERAPEUTICS-SPON ADR (NASDAQ:KZIA) - ChartMill
Kazia Therapeutics (KZIA) director details existing ADS option grants - Stock Titan
Kazia Therapeutics Names Veteran Dealmaker James Levine as CFO to Support Next Phase of Oncology Growth - The Globe and Mail
Kazia Therapeutics (NASDAQ: KZIA) registers 10.7M ADS; names new CFO - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 232,956 ADSs; names new CFO - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 266,666 ADS; names new CFO - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 95,110 ADSs; names new CFO - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) appoints James Levine as new CFO - Stock Titan
KZIAKazia Therapeutics Limited ADR Options - Finviz
Kazia Therapeutics (NASDAQ: KZIA) holder reports 18.5% stake in ADS - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) expands Phase 1b trial, enrollment to 36 patients - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) expands Paxalisib Phase 1b, files prospectus - Stock Titan
Kazia (NASDAQ: KZIA) expands Phase 1b, registers 266,666 ADSs - Stock Titan
Paxalisib breast cancer trial triples size at Kazia (NASDAQ: KZIA) - Stock Titan
Kazia expands paxalisib trial enrollment to 36 patients in TNBC - Investing.com
KZIA Stock Price, Quote & Chart | KAZIA THERAPEUTICS-SPON ADR (NASDAQ:KZIA) - ChartMill
Kazia Therapeutics (KZIA) Chief Scientific Officer Sudha Rao files initial Form 3 - Stock Titan
KZIA | Kazia Therapeutics Limited American Insider Trading - Quiver Quantitative
KZIA SEC FilingsKazia Therapeuti 10-K, 10-Q, 8-K Forms - Stock Titan
How Kazia Therapeutics Ltd (KZIA) Is Strengthening Its Team and Platform - Insider Monkey
Kazia (NASDAQ: KZIA) outlines cancer pipeline and runway to 2029 - Stock Titan
Dr. Sudha Rao joins Kazia Therapeutics (NASDAQ: KZIA) as part-time CSO - Stock Titan
Laidlaw initiates Kazia Therapeutics stock coverage with buy rating - Investing.com
Kazia Therapeutics Expands Oncology Pipeline With SETDB1 Targeted Epigenetic Platform - BioPharma APAC
Kazia Therapeutics (NASDAQ: KZIA) in-licenses SETDB1 platform, pays $1.39M - Stock Titan
Kazia (NASDAQ: KZIA) licenses SETDB1 platform, plans $6M dual-program push - Stock Titan
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform - Bitget
Kazia adds AI-built cancer drug platform with lead candidate MSETC - Stock Titan
Kazia Therapeutics (KZIA) CEO updates ADS option exercise price details - Stock Titan
Kazia Therapeutics (KZIA) executive discloses multiple stock option positions - Stock Titan
95,110 ADS supplement and director exit — Kazia (NASDAQ: KZIA) - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) holder reports 1.59M ADS; 13.90% stake - Stock Titan
Alumni Capital exits KZIA holdings (KZIA) — 0 ADS as of Jan 30, 2026 - Stock Titan
Kazia Therapeutics (KZIA) widens loss yet amasses $69.5m cash and new ATM - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 10.7M ADSs, reports $69.46M cash - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) registers 266,666 ADSs; posts half‑year update - Stock Titan
Kazia Therapeutics (NASDAQ: KZIA) files prospectus supplement for 232,956 ADSs - Stock Titan
Kazia Therapeutics (KZIA) raises major cash despite $12.6m loss - Stock Titan
1.21%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):